Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_09cf654421401ec2aea00d0a5bfa001e http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_4641a9903c3bf57f1e5b30a1880742d0 |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y02A50-30 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-708 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7076 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7042 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-522 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-513 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4745 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-16 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-522 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-513 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4745 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-70 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7076 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-708 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A01N43-04 |
filingDate |
2011-10-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
grantDate |
2012-07-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_406371b1d4179faf66e3e428d54ec905 |
publicationDate |
2012-07-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
US-8211863-B2 |
titleOfInvention |
Administration of TLR7 ligands and prodrugs thereof for treatment of infection by hepatitis C virus |
abstract |
This invention relates to methods for treating or preventing hepatitis C virus infections in mammals using Toll-Like Receptor (TLR)7 ligands and prodrugs thereof. More particularly, this invention relates to methods of orally administering a therapeutically effective amount of one or more prodrugs of TLR7 ligands for the treatment or prevention of hepatitis C viral infection. Oral administration of these TLR7 immunomodulating ligands and prodrugs thereof to a mammal provides therapeutically effective amounts and reduced undesirable side effects. |
isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9050376-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11679141-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11697851-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8790655-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8729088-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11744874-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9359360-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2009202626-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11692005-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11059824-B2 |
priorityDate |
2003-09-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |